Compare Inovio Pharmaceuticals Inc (INO) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs United Microelectronics Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while United Microelectronics Corp trades at $21.21 (market cap $51.00B). The key difference: United Microelectronics Corp is far larger — about 571.3× Inovio Pharmaceuticals Inc's market cap, and United Microelectronics Corp pays a 2.03% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | UMC | |
|---|---|---|
Market Cap | $89.27M | $51.00B |
Sector | Health | Technology |
52-Week High | $2.87 | $28.02 |
52-Week Low | $1.05 | $6.58 |
Enterprise Value | $60.28M | $48.57B |
Dividend Yield | — | 2.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
UMC trades at $20.41, down 3.95% for the day, with a bearish technical signal but oversold RSI readings. The company reported Q1 2026 EPS of $0.20, beating expectations, and maintains strong profitability with a 20.25% net margin. Recent news highlights mass production of silicon photonics ICs and a new 14nm eHV platform, signaling innovation in semiconductor technology.
Outlook is mixed: analyst consensus leans Hold (53%) amid high valuation multiples (P/E 34.5), but earnings beats and specialty tech growth offer upside. Risks include competitive pressures and margin compression from 32.1% in 2022 to 17.0% in 2025. Cash flow improved to $5.66B net in 2025, supporting dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
